Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-synuclein (SNCA) mRNA 5′ untranslated region (UTR) contains a unique, highly conserved iron-responsive element (IRE) that regulates the translation of the SNCA protein in response to intracellular iron levels (Rogers et al., 2011). This RNA stem-loop structure serves as a binding site for iron regulatory protein 1 (IRP-1), which, in its apo-form during low iron conditions, binds the IRE to sterically inhibit the recruitment of the 43S pre-initiation complex, thereby suppressing translation (Muckenthaler et al., 2017). In Parkinson's disease, elevated iron levels in the substantia nigra can lead to the dissociation of IRP-1 from the SNCA IRE, resulting in the overproduction of alpha-synuclein and subsequent neurotoxic aggregation (Ghiglieri et al., 2018). The SNCA IRE–IRP-1 interface has emerged as a therapeutic target for small molecules like Buntanetap (Posiphen), which are designed to stabilize the IRP-1–IRE complex or otherwise inhibit translation to reduce the alpha-synuclein burden (Annovis Bio, 2024). By targeting the regulatory machinery of the mRNA rather than the protein itself, this approach aims to prevent the formation of toxic oligomers at the source. However, a significant challenge in targeting this interface is ensuring specificity, as IRE motifs are also present in the mRNAs of other proteins critical for iron homeostasis, such as ferritin and the transferrin receptor (Moussaud et al., 2015).
Small molecule stabilization of the IRP1-IRE complex or inhibition of ribosomal scanning at the 5' UTR to suppress alpha-synuclein translation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-synuclein mRNA 5′ untranslated region iron-responsive element–iron regulatory protein 1 interface (SNCA IRE–IRP1 interface).